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INTRODUCTION
Renilla luciferase activities using 100 µL of luciferase assay substrate and 100 µL of Stop & Glo reagent of the dual-luciferase reporter assay system (Promega, Madison, CA). Light emission was quantified in a Veritas microplate luminometer using Veritas-version 1.4.0 software (Tuener Biosystems, Sunnyvale, CA). Transfection efficiency of the reporter constructs was controlled by comparison to Renilla luciferase activity. The phRL-TK vector minimized any modulation of Renilla luciferase expression by the experimental conditions since it has been engineered to remove the majority of potential transcription factor binding sites. The luciferase activity of the all promoter-constructs was normalized to a pGL3-basic promoter-less control transfected simultaneously. Four separate transfection sessions were analyzed, and at each session, transfections were performed in triplicate. Three dual luciferase readings were taken for each transfection experiment.
Site-directed mutagenesis of NF-B binding site. Disruption of the NF-B binding site was undertaken using the QuikChange II XL site-directed mutagenesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA). Briefly, for PCR 10ng of pGL3-APS3 was used as a template, and the nucleotide primers listed were used to mutate the NF-B binding site (the bold as wild type, the underline as mutant) of pGL3-APS3: NF B-mutCF: 5' GGTGCTGCACTCAGGCCATCCCTATGAGATCCTC 3' and NF B-mutCR: 5' GAGGATCTCATAGGGATGGCCTGAGTGCAGCACC 3'. After digestion with DpnI, 2 µL of PCR product were used to transform XL10-Gold competent cells. Sequencing identified appropriate clones.
Electrophoretic mobility shift assay (EMSA/gel-shift). The H9c2 cells were treated for 48 h with
AngII or H 2 O 2 , with or without CAPE (caffeic acid phenethyl ester, an NF-B inhibitor at 10µmol/L) starting 24 h after plating. Approximately 5 x 10 6 cells were scraped for nuclear protein extraction by nuclear extract kit (Activemotif, Carlsbad, CA). A double-stranded oligonucleotide containing the consensus-binding sequence (bold) for NF-B (5' GGTGCTGCACTCAGGGGATCCCTATGAGATCCTC 3') and NF-B mutant sequence (5' GGTGCTGCACTCAGGCCATCCCTATGAGATCCTC 3') from scn5a promoter were used as probes to assay for binding activity of the nuclear extracts. Protein-DNA complexes were detected using biotin end-labeled double-stranded DNA probes prepared by annealing complementary oligonucleotides. Oligonucleotides were labeled in a reaction using terminal deoxynucleotide transferase and biotin-N4-CTP (Pierce, Rockford, IL) following the biotin 3' end DNA labeling kit manual. The binding reaction was performed using the LightShift kit (Pierce). Briefly, 30 µg of nuclear extracts and binding buffer were incubated on ice for 5 min in a volume of 20 µL, then the labeled probe (20 fmol) was added, and the reaction was allowed to incubate for an additional 25 min. Following electrophoresis, the DNA-protein complexes were transferred onto nylon membranes and detected using chemiluminescence. TNF-activated H9c2 cell nuclear extract (5 µg) was used as positive control. The reaction products were separated on a 6% retardation gel. Specificity was confirmed by addition of unlabelled probe in 200-fold excess.
Chromatin immunoprecipitation (ChIP) assay. Formaldehyde cross-linking and chromatin immunoprecipitation was performed as described in manufactory's manual (ChIP-IT™ kit, Activemotif). Briefly, proteins were cross-linked with chromatin using 1% formaldehyde in Figure 2 shows that, in comparison with control, 100 nmol/L AngII exposure for 48 h resulted in a 59.6% (± 5.6%, n=9 for control, n=11 in treated group, P<0.001) decrease in peak Na + current. H 2 O 2 exposure (10 µmol/L) for 48 h resulted in a similar 53.8% (± 3.3%, n=9 for control, n=9 in treated group, P<0.01) decrease in peak Na + current.
Steady state channel gating parameters (p>0.05; Fig. 2D&E ) were unchanged between the groups. Nevertheless in the AngII or H 2 O 2 groups, macroscopic inactivation appeared slowed ( Fig. 2A ). As shown in Figure 3A , macroscopic inactivation was well fitted by a single exponential decay. The time constants ( ) of this decay were reduced by 64.7% (± 6.8%, n=11) and 88.2% (± 6.6%, n=9) in the AngII and H 2 O 2 -treated groups respectively as compared to control (n=9; Fig. 3B ). Either treatment resulted in a significant increase in the persistent Na + current at 20 ms (Fig 3C & D) . The reductions in current with AngII or H 2 O 2 were on the order of those seen in the inherited sudden death syndrome, Brugada syndrome (11, 35). (Fig. 6B) .
Overexpression of NF-B subunits in H9c2 cells confirmed the necessity of the p50 subunit for Na + channel downregulation. Quantitative real-time RT-PCR result showed that the relative scn5a mRNA abundances were decreased in cell lines expressing p50 only or the combination of p50 and p65 by 77.3% (± 7.3, n=4) and 88.6% (± 4.8, n=4), respectively. There was no significantly change in Na + channel mRNA in the presence of p65 overexpression alone, however (Fig. 7) .
DISCUSSION
An appropriate number and function of voltage-gated cardiac Na + channels (scn5a) are critical for normal cardiac electrical activity. Either excessive or reduced channel current increases arrhythmic risk. Downregulation of the cardiac Na + channel is seen in heart failure, a condition associated with increased RAS activation (3, 46). Recently, we reported that cardiacrestricted ACE, associated with elevated local AngII levels, can reduce scn5a mRNA abundance.
Nevertheless, it is unclear if AngII mediates these effects, and if so, by what mechanism.
Our experiments suggested that AngII acted through NADPH oxidase -dependent oxidative species and NF-B to reduce Na + channel transcription because 1) the AngII effect was similar to that of H 2 O 2 and was blocked by oxygen radical scavengers or catalase prior to AngII exposure , 2) AngII is known to stimulate NADPH oxidase -dependent reactive oxygen species production in heart (16, 31) and apocynin prevented the effect of AngII, 3) NF-B bound to the channel promoter during treatment with either AngII or H 2 O 2 , 4) mutation of the NF-B binding site prevented the effects of either agent on promoter activity, and 5) overexpression of NF-B recapitulated the effects of either agent. The reduction in Na + current seen with AngII is similar to its effect on other cardiac ion channels, including the transient outward current -subunit Kv4.3 (49), the gap junction protein connexin 43 (14), and the calcium current (12), which may be mediated by a comparable mechanism and also may contribute to enhanced arrhythmic risk in states of increase AngII. The fact that Na + channel transcriptional regulation was affected by NF-B activation is consistent with both the human and mouse Na + channel promoters having a NF-B consensus binding site (GenBank accession numbers AY313163 and AY769981).
Moreover, AngII and H 2 O 2 are known to activate NF-B in cardiomyocytes (5, 17, 28, 33).
Based on the ChIP assay and NF-B subunit overexpression, Na + channel downregulation seems to be mediated by p50 subunit binding to the scn5a promoter.
The chronic effects seen here may be additive with previous reported acute effects of AngII or oxidative stress to enhance Na + channel dysfunction. For example, Na + current was inhibited when cardiac cells were exposed acutely to tert-butyl hydroxyperoxide (2) 
